Skip to content
PICO Portalanswers from OpenAlex

Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease

PaperCitations, authors & open-access status

Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease is a paper indexed in PICO Portal from OpenAlex.

How many citations does Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease have?

PICO Portalcitation count

Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease has 129 citations in the OpenAlex counts PICO Portal stores.

When was Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease published?

PICO Portalyear

Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease has 2019 year in the PICO Portal index.

What is the open-access status of Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease?

PICO Portaloa status

Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease has green oa status in the PICO Portal index.

What is the DOI of Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease?

PICO Portaldoi

The DOI for Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease is on the source record.

What is the PMID of Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease?

PICO Portalpmid

The PMID for Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease is on the source record.

What is the OpenAlex record for Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease?

PICO Portalopenalex

The OpenAlex for Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial